However, when we use these new drugs such as telaprevir and boceprevir we fear that some patients might obtain slow reactions to the drugs or obtain new resistances.
Professor Marcelin: Currently we have the reserves of the phase II studies for some protease inhibitor especially for two protease inhibitors telaprevir and boceprevir.